Favipiravir CAS 259793-96-9 T-705 Purity ≥99.0% (HPLC) COVID-19 API Factory High Quality

Short Description:

Chemical Name: Favipiravir; T-705

CAS: 259793-96-9

Appearance: White to Off-White Powder

Purity: ≥99.0% (HPLC) 

In the treatment of Influenza Virus Infections and COVID-19

API High Quality, Commercial Production 

Inquiry: alvin@ruifuchem.com

Product Detail

Related Products

Product Tags


Chemical Properties:

Chemical Name Favipiravir
Synonyms T-705; 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide
CAS Number 259793-96-9
CAT Number RF-API18
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C5H4FN3O2
Molecular Weight 157.1
Brand Ruifu Chemical


Item Specifications
Appearance White to Off-White Powder
Identification 1H-NMR Consistent with proposed structure
Identification HPLC Retention time of main peak in sample preparation should be correspond with the retention time of main peak in reference standard preparation
Identification Mass Mass Spectrum is consistent with proposed structure
Melting Point 188.0℃-193.0℃
Related Substances 
(Area Normalization)
Any Single Impurity: ≤0.10% (HPLC)
Total Impurities: ≤1.0% (HPLC)
Purity / Analysis Method ≥99.0% (HPLC)
Moisture (K.F) ≤0.50% 
Residue on Ignition ≤0.10%
Heavy Metals ≤20ppm
Residue Solvents
Methanol ≤3000ppm
Isopropanol ≤5000ppm
n-Heptane ≤5000ppm
Ethanol ≤5000ppm
Test Standard Enterprise Standard
Usage Active Pharmaceutical Ingredient (API); Treatment of COVID-19

Package & Storage:

Package: Bottle, Aluminum foil bag, 25kg/Cardboard drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.





Favipiravir (T-705) (CAS 259793-96-9) is one of the 5 compounds recommended by WHO for the investigation of treatment of COVID-19. Favipiravir is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Favipiravir is a broad-spectrum antiviral drug that was cleared by the Drugs Controller General of India (DCGI) last week for “emergency restricted” use among Covid-19 patients. Favipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza.

  • Write your message here and send it to us